All News Top News Sep 18, 2018 Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement Learn More Share Top News Sep 14, 2018 Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults Learn More Share Top News Sep 14, 2018 Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection Learn More Share Top News Sep 12, 2018 Teva to Present at the Morgan Stanley Global Healthcare Conference Learn More Share Top News Sep 4, 2018 Teva Announces $400 Million Debt Tender Offer Learn More Share
Top News Sep 18, 2018 Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement Learn More
Top News Sep 14, 2018 Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults Learn More
Top News Sep 14, 2018 Teva Announces U.S. Approval of AJOVY (TM) (fremanezumab-vfrm) Injection Learn More